Benefits
Blood lipid oxidation: lower oxidized LDL in a 16-week placebo trial
In a 16-week randomized, double-blind trial in 49 adults aged 40 to 70 with overweight and prediabetes, 15 mg of hydroxytyrosol a day lowered oxidized LDL, the main outcome, compared with placebo (p = 0.045). Blood lipid levels did not change. A one-week trial of 5 or 25 mg a day found no change in blood lipids or oxidation markers.
Blood lipid protection: an EU claim for olive oil, not capsules
The EU authorizes the claim that olive oil polyphenols contribute to the protection of blood lipids from oxidative stress, but only for olive oil with at least 5 mg of hydroxytyrosol and its derivatives per 20 g, eaten at 20 g a day. In a trial in 200 healthy men, oxidized LDL fell as the polyphenol content of olive oil rose. The claim does not cover supplements.
Antioxidant status: gains in some small trials, none in others
In the 16-week prediabetes trial, 15 mg a day lowered protein carbonyls and the DNA oxidation marker 8-OHdG and kept total antioxidant status and glutathione peroxidase from falling, versus placebo. A 3-week crossover trial of 15 mg a day in 28 healthy adults reported higher antioxidant status and lower malondialdehyde. A one-week trial at 5 or 25 mg found no change.
Blood vessel function: small, short trials with mixed results
In a 1-month crossover trial in 30 people with chronic coronary artery disease, olive oil capsules giving 10 mg of hydroxytyrosol a day improved flow-mediated dilation and arterial stiffness versus baseline, while placebo did not; blood pressure did not change. A 30-day crossover trial in 61 similar patients at 10 mg a day found no significant change in heart or artery measures.
Inflammation markers: a borderline IL-6 drop in one trial
In the 16-week prediabetes trial, the inflammation marker IL-6 fell more on 15 mg of hydroxytyrosol a day than on placebo (p = 0.05). A one-week trial at 5 or 25 mg a day found no change in inflammation markers, and an 8-week study at 45 mg a day found little change. Effects on inflammatory signaling seen in lab and animal work have not been confirmed in people.
Urine hydroxytyrosol markers linked to longevity in diet studies
Observational diet data only. In 1,851 older Spanish adults at high cardiovascular risk, more urine homovanillyl alcohol, hydroxytyrosol's methylated metabolite, went with lower total mortality; hydroxytyrosol itself only with fewer cardiovascular events (paper later corrected). In a 256-person diet trial, more urine hydroxytyrosol went with slower aging on one epigenetic clock. No supplement trial of aging or lifespan was found.
Body weight: early small losses that faded by six months
In a 6-month randomized trial in 29 women with overweight or obesity, all on a reduced-calorie Mediterranean diet, 15 mg of hydroxytyrosol a day led to more weight and visceral fat loss than placebo at 4 weeks, but the difference faded by 12 and 24 weeks. A 3-week crossover trial found a 0.46 percent weight drop, and the 16-week prediabetes trial found no change in weight.
Mechanism of action
Free-radical scavenging (lab chemistry)
The catechol (ortho-diphenol) ring of hydroxytyrosol lets it donate electrons to reactive oxygen species in laboratory tests. How much of this happens in the body is uncertain, because swallowed hydroxytyrosol peaks in blood within about 30 minutes and is largely converted to metabolites such as hydroxytyrosol sulfate and homovanillic acid.
Nrf2 signaling (not confirmed in a human trial)
In cell and animal studies hydroxytyrosol switches on Nrf2, a switch for the body's own antioxidant enzymes. In a one-week placebo-controlled human trial, 5 or 25 mg a day did not change Phase II enzyme expression in blood immune cells.
Endothelial nitric oxide (lab and early human data)
Lab studies suggest hydroxytyrosol supports endothelial nitric oxide production, but this has not been measured directly in people. One small crossover trial of hydroxytyrosol-enriched olive oil capsules improved flow-mediated dilation versus baseline, while a second similar trial found no significant change.
Protecting LDL from oxidation
Hydroxytyrosol and other olive polyphenols are thought to protect LDL particles from oxidative damage. In people, oxidized LDL fell with higher-polyphenol olive oil, with 15 mg a day of hydroxytyrosol for 16 weeks versus placebo, and with 10 mg a day in olive oil capsules versus baseline, but did not change in a 3-week crossover trial of 15 mg a day. A one-week trial found no change in oxidation markers.
Clinical trials
Randomized crossover trial at 6 centers in 5 European countries. Participants took 25 mL a day of three olive oils that differed in phenolic content (low, medium, high), each for 3 weeks with 2-week washouts. This tested whole olive oils, not hydroxytyrosol supplements. (Covas et al. 2006, Annals of Internal Medicine)
200 healthy men
HDL cholesterol rose linearly with phenolic content (by 0.025, 0.032 and 0.045 mmol/L), the total to HDL cholesterol ratio fell linearly, and oxidative stress markers fell linearly. Oxidized LDL fell significantly only on the high-polyphenol oil (by 3.21 U/L). Triglycerides fell by 0.05 mmol/L on all three oils.
Randomized, double-blind, placebo-controlled parallel trial (NCT06295913) run by the Spanish National Research Council. Participants took 15 mg of hydroxytyrosol or placebo daily for 16 weeks; oxidized LDL was the primary outcome. The registration describes a hydroxytyrosol-rich extract capsule and lists Genosa I+D, an olive extract maker, as collaborator. (Moratilla-Rivera et al. 2025, Clinical Nutrition)
49 adults aged 40 to 70 with overweight and prediabetes (52 randomized)
Compared with placebo, hydroxytyrosol lowered oxidized LDL (p = 0.045), protein carbonyls (p = 0.031) and 8-OHdG (p < 0.01), prevented falls in total antioxidant status and glutathione peroxidase, and lowered IL-6 (p = 0.05). Blood lipids, body measurements, sleep, mental well-being and physical capacity did not change. No adverse events were seen.
Double-blind, randomized, placebo-controlled trial in a Latin square design (NCT02273622) at IMDEA Food, Madrid. Participants took 5 mg or 25 mg of hydroxytyrosol a day, or placebo, for one week each. (Crespo et al. 2015, Pharmacological Research)
20 healthy men aged 20 to 40 (per the trial registration)
Hydroxytyrosol was well tolerated but did not significantly change Phase II antioxidant enzyme expression in blood immune cells, the main outcome. The authors also found no significant effect on blood lipids or on inflammation and oxidation markers.
Randomized, double-blind, placebo-controlled trial (NCT04317079) in Athens. Participants took capsules of an olive debittering-water extract standardized to 2.5 mg hydroxytyrosol each, giving 15 or 5 mg a day, or placebo, for 6 months; all followed a personalized reduced-calorie Mediterranean diet. Weight and fat mass were the primary outcomes. One co-author was from Uni-Pharma, an Athens pharmaceutical company. (Fytili et al. 2022, Nutrients)
29 women with overweight or obesity analysed (37 randomized)
At 4 weeks, the 15 mg group lost more weight (p = 0.012) and visceral fat (p = 0.006) than placebo, but these differences weakened at 12 and 24 weeks. Hydroxytyrosol was safe and well tolerated.
Randomized, double-blind, placebo-controlled crossover trial at the University of Rome Tor Vergata. Participants took two gastro-resistant capsules giving 15 mg of hydroxytyrosol a day, or placebo, for 3 weeks each. (Colica et al. 2017, Oxidative Medicine and Cellular Longevity)
28 healthy adults aged 18 to 65 who completed (40 enrolled)
After hydroxytyrosol, total antioxidant status and thiol groups rose and malondialdehyde, nitrite and nitrate fell; body fat percentage and weight dropped slightly (weight by 0.46 percent). Oxidized LDL, total cholesterol, HDL cholesterol and triglycerides did not change.
Prospective, double-blind, placebo-controlled crossover trial in Athens. Participants took 4 capsules a day, each with 412.5 mg olive oil and 2.5 mg hydroxytyrosol (10 mg a day), or placebo, for 1 month each. One co-author was from Intermed, an Athens company. (Ikonomidis et al. 2023, European Journal of Clinical Investigation)
30 adults with chronic coronary artery syndrome
Compared with baseline, the hydroxytyrosol capsules improved flow-mediated dilation, coronary flow reserve, pulse wave velocity and sublingual glycocalyx thickness, and lowered malondialdehyde, oxidized LDL, triglycerides, PCSK9 and CRP, while placebo had no effect. Blood pressure did not change.
Randomized two-period crossover trial in Greece. Participants took two 500 mg olive oil extract capsules a day, each with 5 mg hydroxytyrosol (10 mg a day), or placebo, for 30 days each with a 48-hour washout. (Iakovis et al. 2023, Journal of Medicinal Food)
61 adults with chronic coronary artery disease
No significant change in left atrial or ventricular function, ejection fraction, central aortic pressure or augmentation index. Only trends toward better diastolic function (p = 0.062) and pulse wave velocity (p = 0.091) were seen.
Uncontrolled before-and-after study (no placebo group). Participants took 45 mg a day of hydroxytyrosol purified to 99.5 percent from olive mill waste for 8 weeks. One author worked for Biosearch Life, an ingredient company. (Lopez-Huertas and Fonolla 2017, Redox Biology)
14 adults with mildly raised blood lipids
Hydroxytyrosol mostly did not change cardiovascular markers, blood lipids, inflammation markers, or liver and kidney function. Vitamin C doubled at 4 and 8 weeks versus baseline, while ferritin and folate fell. Without a control group these changes cannot be attributed to hydroxytyrosol.
Meta-analysis of randomized controlled trials of supplementation with oleuropein, hydroxytyrosol or tyrosol; not a single trial, and the three compounds were pooled. (Frumuzachi et al. 2025, Critical Reviews in Food Science and Nutrition)
14 human intervention studies, 594 participants
Pooled results showed small reductions in total cholesterol (SMD -0.19), triglycerides (SMD -0.32) and insulin (SMD -0.42), with moderate to high variation between studies for triglycerides and insulin. The authors call for further studies to confirm the findings.